Jefferies Group LLC Analysts Give Pfizer, Inc. (PFE) a $39.00 Price Target

Jefferies Group LLC set a $39.00 target price on Pfizer, Inc. (NYSE:PFE) in a research note published on Thursday morning. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other research firms also recently weighed in on PFE. BMO Capital Markets restated a buy rating and issued a $39.00 price target on shares of Pfizer in a research note on Friday, November 10th. J P Morgan Chase & Co set a $39.00 price target on shares of Pfizer and gave the company a buy rating in a research note on Wednesday, November 1st. Goldman Sachs Group, Inc. (The) set a $36.00 price target on shares of Pfizer and gave the company a neutral rating in a research note on Wednesday, November 1st. UBS AG set a $38.00 price target on shares of Pfizer and gave the company a buy rating in a research note on Wednesday, November 1st. Finally, Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the company a neutral rating in a research note on Tuesday, October 31st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $38.48.

Shares of Pfizer (PFE) traded down $0.19 during trading on Thursday, reaching $35.37. 14,817,055 shares of the company’s stock were exchanged, compared to its average volume of 15,641,362. The firm has a market capitalization of $210,830.20, a P/E ratio of 14.15, a price-to-earnings-growth ratio of 2.50 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a 12-month low of $30.51 and a 12-month high of $36.78.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the prior year, the company posted $0.61 earnings per share. research analysts forecast that Pfizer will post 2.6 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Jefferies Group LLC Analysts Give Pfizer, Inc. (PFE) a $39.00 Price Target” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://ledgergazette.com/2017/11/19/jefferies-group-llc-analysts-give-pfizer-inc-pfe-a-39-00-price-target-2.html.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.62%. Pfizer’s payout ratio is 79.01%.

In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Laurie J. Olson sold 8,064 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the transaction, the insider now owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 374,621 shares of company stock valued at $12,796,098. Company insiders own 0.06% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in PFE. Vanguard Group Inc. increased its stake in shares of Pfizer by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Pfizer by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Pfizer by 0.9% in the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after acquiring an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Pfizer by 4.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after acquiring an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC increased its stake in shares of Pfizer by 3.2% in the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after acquiring an additional 1,085,437 shares in the last quarter. Hedge funds and other institutional investors own 69.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply